Treatment of Moderate to Severe Atopic Dermatitis
common.study.values.description
“A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis”
This is a phase 3, randomized, multi-center study that will evaluate upadacitinib versus dupilumab in adults (18-75 years of age) with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy. The study is comprised of a 35-day screening period, a 24-week blinded treatment period, and a 12-week follow-up period.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - Upadacitinib (ABT-494)
Upadacitinib is administered orally
Drug - Dupilumab
Dupilumab is administered as a subcutaneous (SC) injection
Drug - Placebo
Placebo pre-filled syringe is administered as subcutaneous (SC) injections
Drug - Placebo
Placebo tablets are administered orally
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
common.study.values.clinical-trial-id
NCT03738397
participant.views.study.view.id
bDkYna
